A total of 636 vancomycin-resistant Enterococcus faecium (VRE) isolates that had been obtained between 1994 and 1999 from the Medical School Hospital of the University of Michigan, Ann Arbor, were tested for bacteriocin production. Two hundred seventy-seven (44%) of the strains were bacteriocinogenic; and 193 of these exhibited activity against Enterococcus faecium, Enterococcus hirae, and Enterococcus durans. Strain VRE200 harbors the highly efficient conjugative gentamicin resistance plasmid pG200 (70 kb) and bacteriocin plasmid pTI1 (12.5 kb). The bacteriocin encoded on pTI1 was designated bacteriocin 32 (Bac 32). Bacteriocin 32 was active against E. faecium, E. hirae, and E. durans but showed no activity against Listeria monocytogenes. The Bac 32 genetic locus consists of a bacteriocin gene (bacA) and an immunity gene (bacB). Neither of these genes showed significant homology to any known bacteriocin determinants. The deduced bacA product is 89 amino acids in length, with a putative signal peptide of 19 amino acids at the N terminus. The bacB gene encodes a deduced 55-amino-acid protein without a signal sequence. One hundred eighty-nine strains (97.9%) of the 193 strains with activity against the 3 test enterococcal strains gave rise to the expected specific PCR product with a primer specific for bacA, indicating that there is a high incidence of Bac 32 production among VRE clinical isolates. Data from Southern analyses of plasmid DNA from 189 of the Bac 32-producing strains with a plasmid pTI1-specific probe suggested that 137 (72.5%) of the strains harbored a pTI1-type plasmid. Bac 32 or Bac 32-type bacteriocin activity and the determinant genes were also identified in 22 (39.3%) of a total of 56 vancomycin-sensitive E. faecium clinical isolates, which suggests that this bacteriocin is widely disseminated among E. faecium strains.
Multiple-drug-resistant enterococci and vancomycin-resistant enterococci (VRE) in particular are major causes of nosocomial infection. The acquired glycopeptide resistance provided by VanA has predominantly been identified in Enterococcus faecium isolates (23, 31, 46) . Multiple resistance to commonly used antibiotics provide these organisms with a selective advantage within environments, such as the health care environment for humans (23, 34) or the food animal production environment (2, 29, 39, 47) , where antibiotics are used. The direct selective pressure of antimicrobial agents is the largest contributing factor in the selective increase of multiple-drug-resistant enterococci in different habits. However, the ecological factors influencing the proliferation of the organisms involved in these epidemiological scenarios have not yet been elucidated.
Bacteriocins are produced by a wide variety of gram-positive and gram-negative bacteria. They are bacterial proteins which inhibit the growth of other bacteria that are closely related to the producer strain, and they usually exhibit a relatively narrow spectrum of activity. Bacteriocins are thought to provide the producer strain with an ecological or selective advantage over other strains. Bacteriocin production has been described for several genera of lactic acid bacteria (LAB) (13) . LAB bacteriocins can be divided into two main classes (36) : class I consists of modified bacteriocins (the lantibiotics); and class II consists of the small heat-stable nonlantibiotics. Class II bacteriocins are further divided into subgroup IIa, which are pediocin-like bacteriocins with strong antilisteria effects, and subgroup IIb, which are non-pediocin-like bacteriocins and those with two peptides that require the complementary actions of both peptides for full antimicrobial activity. Enterococcus faecalis and E. faecium bacteriocins have been genetically and biochemically well characterized in the genus Enterococcus. E. faecalis bacteriocins include the ␤-hemolysin/bacteriocin (cytolysin) (9, 11, 18, 20, 25, 26) , the peptide antibiotic AS-48 (33) , bacteriocin 21 (Bac 21) (44) , and bacteriocin 31 (43) . These E. faecalis bacteriocins have been identified in clinical isolates (9, 32, 43, 44) . The well-characterized E. faecium bacteriocins have been identified from food-grade organisms (8) . These include enterocins A (1), B (3), P (7), I (15) , and L50A and L50B (6) . These bacteriocins belong to LAB class II bacteriocins and are active against Listeria monocytogenes (36) . Enterocins A and P are pediocin-like bacteriocins (36) .
In contrast to the bacteriocins obtained from E. faecalis clinical isolates, little is known about the bacteriocins present in E. faecium clinical isolates. In this report, we describe the high level of incidence of a specific bacteriocin in both vancomycin-resistant and vancomycin-sensitive E. faecium clinical isolates.
MATERIALS AND METHODS
Bacteria, media, and reagents. The laboratory strains and plasmids used in this study are listed in Table 1 . A total of 640 vancomycin-resistant Enterococcus faecium (VRE) clinical isolates were obtained from different patients who had been admitted to the University of Michigan Medical School Hospital, Ann Arbor, between 1994 and 1999 (45) . Of the 640 VRE clinical isolates, 636 isolates were used in this study. Fifty-six vancomycin-sensitive E. faecium clinical isolates and 56 vancomycin-sensitive E. faecalis clinical isolates were included in the study. These strains were obtained from different patients at the Gunma University School of Medicine Hospital, Maebashi, Gunma, Japan, between 1990 and 1993. Forty-six E. faecium nonclinical isolates were obtained from the feces of healthy students attending Gunma University School of Medicine, Maebashi, Japan, in 2002 and 2003. Enterococcal strains were grown in Todd-Hewitt broth (THB; Difco, Detroit, MI) or antibiotic medium 3 (Difco). Escherichia coli strains were grown in Luria-Bertani medium. Solid and soft media were prepared by the addition of 1.5 or 0.75% (wt/vol) agar, respectively. All cultures were grown at 37°C. The following antibiotics were used at the indicated concentrations: ampicillin, 100 g/ml; chloramphenicol, 20 g/ml for enterococci and 50 g/ml for E. coli; rifampin, 25 g/ml; fusidic acid, 25 g/ml; streptomycin, 500 g/ml; spectinomycin, 500 g/ml for enterococci and 50 g/ml for E. coli; kanamycin, 40 g/ml; tetracycline, 12.5 g/ml; vancomycin, 5 g/ml; and gentamicin, 200 g/ml.
Soft-agar assay for bacteriocin production and immunity. The bacteriocin production assay was performed as described previously (26) . The test for immunity to the bacteriocin was performed essentially as described previously (26) .
Conjugative transfer and mobilization experiments. Broth mating was performed as described previously (14, 25) , with a donor/recipient ratio of 1:10. Colonies were counted after 48 h of incubation at 37°C. Solid-surface mating was performed on agar plates. The mating mixture of donor and recipient was made as described above for the broth matings, and 10 l of the mixed culture was spotted onto THB agar without antibiotics. The plates were then incubated overnight at 37°C. After incubation, the bacteria that had grown on the agar plates were scraped off and transferred into 1 ml of fresh THB, and then 0.1 ml of the mixture was spread onto appropriate selective agar plates. The colonies were counted after 48 h of incubation at 37°C. The conjugative transfer frequency was calculated as the ratio of the number of transconjugants to the number of donors. The mobilized transfer frequency was calculated as the ratio of the number of transconjugants which showed bacteriocin activity to the number of donors.
Isolation and manipulation of plasmid DNA. Plasmid DNA was isolated by the alkaline lysis method (37) . Plasmid DNA was treated with restriction enzymes and subjected to agarose gel electrophoresis for analysis of DNA fragments, etc. Restriction enzymes were obtained from Nippon Gene (Toyama, Japan); New England Biolabs, Inc.; and Takara (Tokyo, Japan). They were used in accordance with the suppliers ' specifications. Agarose was obtained from Wako Chemicals, Osaka, Japan. Electrophoresis on 0.8% agarose gels was used to determine the size of large DNA fragments (those larger than 0.5 kb), and 2.0% agarose gels were used for analysis of small fragments (those smaller than 0.5 kb) (17) . A "glass milk" kit (Gene Clean II kit; Bio 101, Inc., La Jolla, CA) was used for the elution of DNA fragments from agarose gels. The eluted fragments were ligated to dephosphorylated, restriction enzyme-digested vector DNA with T4 DNA ligase and were then introduced into E. coli by electrotransformation (16) . Transformants were selected on Luria-Bertani medium agar containing the appropriate antibiotics.
DNA sequence analysis. Nucleotide sequences were obtained as described previously (38) . A deletion kit (Nippon Gene) was also used. To determine the sequence of plasmid pTI1, HindIII-B and -D fragments were cloned into the vector pBluescript-SK(ϩ). Each of the cloned DNA fragments was digested with BamHI and SacI or KpnI and XhoI and then treated with exonuclease III for various periods of time, followed by treatment with mung bean nuclease and then the Klenow fragment. The deleted DNAs were self-ligated with T4 DNA ligase. The ligation product was used to transform E. coli DH5␣. The resulting constructs were sequenced in both orientations by using a model 377 DNA sequencer (Applied Biosystems) with Taq Dye Primer and Taq BigDye Terminator cycle sequencing kits (Applied Biosystems). The remaining regions and gapped regions were sequenced directly by using the appropriate primers. A database search was performed by using the BLASTn and tBLASTx programs of the National Center for Biotechnology Information, Bethesda, MD (http://www.ncbi .nlm.nih.gov). Cloning of pTI1 bacA and bacB. To determine the bacteriocin determinant (bacA) and the immunity determinant (bacB) of the bacteriocin, a set of pAM401-based clones containing various DNA fragments of pTI1 was constructed. Each of the EcoRI fragments and the EcoRV fragments of pTI1 was separated by agarose gel electrophoresis and cloned into the EcoRI and EcoRV sites of pAM401, respectively. A clone harboring the EcoRV-NruI fragment, which mapped between 3.6 kb and 7.3 kb, was constructed as follows. The clone containing EcoRV fragment A was partially digested with a low concentration of NruI and then self-ligated. Each cloned plasmid DNA was prepared from E. coli and used to transform E. faecalis FA2-2 to test for bacteriocin activity or Enterococcus hirae ATCC 9790 to test for immunity to the bacteriocin. A variety of amplified PCR products were also cloned for further detailed study.
Generation of transposon (Tn5) insertion mutants. Tn5 (Km r ) insertion into the cloned plasmid DNA was performed as described elsewhere (41) . Target plasmid pMG403 (plasmid pAM401 containing EcoRV fragment A) was introduced into E. coli K-12 TH688 (with Tn5 in the thr locus) by electrotransformation. Transformants were spread onto selective plates containing kanamycin and chloramphenicol, and the plates were left at room temperature for 10 days. The bacteria that grew on the selective plates were pooled, and the plasmid DNA was then isolated and used to transform E. coli DH5␣. The transformants were selected on plates containing kanamycin and chloramphenicol for the selection of Tn5-mediated kanamycin resistance and plasmid-mediated chloramphenicol resistance, respectively. The transformants were purified and examined to determine the location of Tn5 within the plasmid. The precise locations of Tn5 insertion were determined by DNA sequence analysis by using a synthetic primer that hybridized to the end of Tn5.
PCR amplification and overlap extention PCR techniques. PCR amplification was performed by using the thermostable DNA polymerase TaKaRa Taq (Takara Bio Inc.) and a Perkin-Elmer 9600 thermal cycler. The PCR conditions varied according to the primers used and the size of the anticipated product. The custom primers used in this study were obtained from Invitrogen (Tokyo, Japan) and are listed in Table 2 . All primers were designed to incorporate a restriction enzyme recognition site at the 5Ј end to facilitate cloning of the PCR products into the identical site within the vector plasmids. All clones were sequenced in both orientations to confirm that they conformed to the desired structures. Site-directed mutagenesis was performed by overlap extension PCR. The procedures used were based on those described previously (21) . Complementary oligonucleotide primers incorporating nucleotide changes were prepared to generate two DNA fragments with overlapping ends in the first round of PCR amplification. Specific mutations could be introduced by the subsequent fusion of the two fragments during the second round of PCR amplification. The resulting fusion product was used for cloning.
Pulsed-field gel electrophoresis. A gel block containing genomic DNA was digested with 10 U of SmaI overnight. Electrophoresis was then carried out in a 1% agarose gel with 45 mM Tris-borate and 1 mM EDTA, and the following settings were applied: 1 to 21 s, 6 V/cm 2 , and 20 h. The gel was stained with ethidium bromide for UV observation.
DNA-DNA hybridization. Southern hybridization was performed with the digoxigenin-based nonradioisotope system of Boehringer GmbH (Mannheim, Germany), and all procedures were based on the manufacturer's manual and standard protocols (37) . The plasmid DNA was isolated and digested with EcoRI. Hybridization was performed overnight at 42°C in the presence of 50% formamide. To make a probe for the detection of whole pTI1 plasmid DNA, a mixture of the purified DNAs of EcoRI fragments A and B of pTI1 from the deletion mutants was used. The probes were generated by using a DIG probe synthesis kit (Roche Diagnostics GmbH, Mannheim, Germany). The signals were detected with nitroblue tetrazolium-5-bromo-4-chloro-3-indolylphosphate stock solution (Roche Diagnostics GmbH).
Nucleotide sequence accession number. The nucleotide sequence data reported in this article are available from nucleotide sequence databases under accession number AB205024.
RESULTS

Bacteriocinogenic strains of vancomycin-resistant Enterococcus faecium clinical isolates. A total of 636 vancomycin-resistant
Enterococcus faecium strains were tested for bacteriocin production against the indicator strains Staphylococcus aureus FDA209P, Enterococcus faecalis FA2-2 (42) and OG1-10 (14), Enterococcus faecium BM4105RF, Enterococcus hirae ATCC 9790, Enterococcus durans ATCC 49135, Enterococcus raffino- ) in order to examine whether bacteriocin production was reliant on the presence of a plasmid. Gentamicin resistance (Gm r ) was used as a selective marker for the transconjugants since VRE200 also harbored the pMG1-like conjugative plasmid pG200 (Gm r ; 70 kbp) (45), and rifampin and fusidic acid were used for counterselection against the donor strain. Gentamicin-resistant transconjugants were tested for bacteriocin activity against E. faecium, E. hirae, and E. durans. About 40% of the transconjugants showed bacteriocin activity identical to that of donor strain VRE200 with respect to the size of the bacteriolysis zone, and the remaining transconjugants showed no bacteriocin activity. Plasmid DNA was isolated from each of the transconjugants, treated with restriction enzymes, and analyzed by agarose gel electrophoresis. All of the nonbacteriocinogenic gentamicin-resistant transconjugants harbored only the pG200 plasmid. However, all bacteriocinogenic gentamicin-resistant transconjugants harbored an additional plasmid DNA with a molecular size of 12.5 kbp, which was designated pTI1. These results implied that pTI1 (12.5 kbp) conferred on its host strain the ability to produce bacteriocin. pTI1 was mobilized in strains of E. faecium, E. hirae, and E. faecalis by the pG200 plasmid at a high frequency of about 10 Ϫ3 in broth mating and conferred the ability to produce bacteriocin on these enterococcal strains. Repeated experiments involving broth and solid-surface matings, as well as curing and electrotransformation techniques, failed to produce isolates carrying only pTI1.
E. faecium and E. faecalis strains containing pTI1 expressed bacteriocin activity against E. faecium, E. hirae, and E. durans, unlike bacteriocin 31, which is encoded on the E. faecalis bacteriocin plasmid, pYI17, and is active against E. faecium, E. hirae, E. durans, and L. monocytogenes (43) . Plasmid pMG110 is pAM401 carrying a 7.9-kbp fragment of pYI17 that contains the Bac 31 determinant. E. hirae ATCC 9790(pTI1) showed bacteriocin activity against E. hirae ATCC 9790(pMG110) and vice versa (data not shown). These results suggested that the bacteriocin encoded on pTI1 differs from bacteriocin 31 based on its bacteriocin spectrum and the immunity against its own bacteriocin. The bacteriocin encoded on pTI1 was designated bacteriocin 32.
DNA sequence of bacteriocin plasmid pTI1. The DNA sequence of pTI1 was determined and was found to be 12,463 bp in length. Computer analysis revealed the presence of 18 open reading frames (ORFs) in pTI1, and all were oriented in the same direction. Figure 1a shows the ORFs which had a good ribosome binding site within a 20-base region upstream of the predicted start codon.
Comparison of the amino acid sequences and the nucleotide sequences of the pTI1 ORFs did not reveal homology to known bacteriocin-related or immunity-related proteins.
Cloning of the bacteriocin determinant of pTI1. The following recombinant plasmids conferred bacteriocin activity on the E. faecalis strain (Fig. 1b) : a plasmid containing the SalI fragment (pMG401), which included all of pTI1 (12.5 kb); a plasmid containing EcoRI fragment A (pMG402), which is deleted between 6.1 kb and 10.9 kb of pTI1; or a plasmid containing EcoRV fragment A (pMG403), which is deleted between 0.2 kb and 3.6 kb of pTI1. The clone of an EcoRI-NruI fragment (pMG404) that carries the region between 3.6 kb and 7.3 kb of pTI1 did not confer bacteriocin activity. These results implied that the determinant for bacteriocin 32 is not located between 0.2 kb and 10.9 kb of the pTI1 map but could be between the EcoRI site at 10.8 kb and the SalI site at 12.5 kb on the map (Fig. 1b) .
Analysis of Tn5 insertion mutants. For detailed analysis of the determinant for bacteriocin 32, Tn5 insertion mutants of clone pMG403 containing EcoRV fragment A were generated. A total of 40 insertions in the cloned segment were obtained (Fig. 1c) , and three of these resulted in the loss of bacteriocin activity, while activity was retained by the remaining 37. The three nonbacteriocinogenic mutants, designated pMG403-33, pMG403-34, and pMG403-35, were mapped at positions 11,009 bp, 11,027 bp, and 11,056 bp, respectively, within ORF14 (Fig. 1c) . pMG403-33, pMG403-34, and pMG403-35 were introduced into E. hirae ATCC 9790 to test for immunity to the bacteriocin. VRE200 did not show bacteriocin activity against ATCC 9790(pMG403-33), ATCC 9790(pMG403-34), or ATCC 9790 (pMG403-35), indicating that the mutants expressed immunity.
Mutants pMG403-31 and pMG403-32 or mutants pMG403-36 and pMG403-37, which expressed bacteriocin activity, were located the closest to the nonbacteriocinogenic mutants and mapped to positions 10,745 bp and 11,659 bp, respectively, on either side of the nonbacteriocinogenic mutants. These results indicated that the 0.9-kb span of DNA segment that mapped between 10,745 bp and 11,659 bp of pTI1 was required to express bacteriocin 32 (Fig. 1c) . The 0.9-kb DNA segment contained ORF14 and ORF15.
Cloning of PCR products conferring bacteriocin production. To determine the precise region that conferred bacteriocin production, PCR products incorporating segments of the 0.9-kb region of pTI1 encoding ORFs 14 and 15 were used. These recombinant plasmids were used to transform E. faecalis FA2-2, which is not sensitive to Bac 32, or E. hirae ATCC 9790, which is sensitive to Bac 32, followed by selection for resistance to chloramphenicol (encoded by pAM401). Chloramphenicolresistant transformants were then examined for bacteriocin activity. The results are shown in Fig. 1d . on September 7, 2017 by guest http://aac.asm.org/ pMG405 carries a 908-bp fragment that contains both ORF14 and ORF15. E. faecalis FA2-2 and E. hirae ATCC 9790 strains containing pMG405 expressed bacteriocin activity and immunity. pMG406 and pMG407 contain only ORF14. E. faecalis FA2-2 was transformed with pMG406 and pMG407, and the transformants expressed bacteriocin activity. E. hirae ATCC 9790 could not be transformed with pMG406 and pMG407, suggesting that these plasmids did not confer immunity. The insert in pMG408 corresponds to a fragment that has an 18-bp deletion in the C-terminal region of ORF14 of pMG407. The insert in pMG409 corresponds to the fragment with a deletion of 16 bp in the N-terminal region of ORF14 of pMG407. E. faecalis FA2-2 and E. hirae ATCC 9790 strains carrying pMG408 or pMG409 did not express bacteriocin activity, and the E. hirae ATCC 9790 strain did not express immunity to the bacteriocin activity of E. faecalis FA2-2(pMG401).
The 489-bp insert fragment of pMG411 contains the 37 bp C-terminal region of ORF14 and the complete ORF15. The 703-bp insert fragment of pMG410 has a 16-bp deletion in the N-terminal region of ORF14 and contains the complete ORF15. E. faecalis FA2-2 and E. hirae ATCC 9790 strains containing pMG410 or pMG411 did not express bacteriocin activity, but the E. hirae ATCC 9790 strains expressed immunity to the bacteriocin activity of E. faecalis FA2-2(pMG401).
These results indicate that ORF14 encodes the bacteriocin and that ORF15 encodes immunity against this bacteriocin. The fragment containing both ORF14 and ORF15 conferred bacteriocin activity and immunity on the E. hirae strain. ORF14 and ORF15 were designated bacA and bacB, respectively. The bacteriocin was active against E. hirae, E. faecium, and E. durans but not E. faecalis.
bacA encodes an 89-amino-acid protein. The TTG start codon was preceded by a potential Shine-Dalgarno (S.D.) ribosome binding site (AAAGGAG) at a location 10 bp upstream. There was no homology between bacA and any reported bacteriocin genes. Computer analysis suggested that the deduced bacA protein had a signal peptide sequence, and a potential signal peptidase processing site corresponding to the L-L-A sequence was located at positions 17 to 19 (Fig. 2) . bacB encoded a 55-amino-acid protein. The ATG start codon Boldface letters in the amino acid sequence, potential signal peptidase processing site; arrows with the identification number for pMG407 at nucleotide positions 1 and 398, the respective left and right end nucleotides of the 398-bp fragment contained in plasmid pMG407, which was cloned into pAM401. pMG407 was used to construct mutants by overlap extension PCR. Arrow with a numbered shaded circle, the point of Tn5 insertion that abolished bacteriocin expression; nucleotide(s) shown in boxes beside the identification number for the plasmids, substitutions or deletions of the nucleotide(s); nucleotides and arrows within parentheses, nucleotide substitution.
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was preceded by a potential ribosome binding site (AAGGAG) located 11 bp upstream. There was no homology with any known immunity genes for bacteriocins or any other reported genes.
Mutational analysis of ORF14 (bacA) by overlap extension PCR method. To confirm that bacA determined bacteriocin expression, mutants of bacA were constructed by the overlap extension PCR method. The mutants were constructed by using pMG407, and the mutant plasmids were then used to transform E. faecalis FA2-2 to examine bacteriocin activity. The results are shown in Fig. 2 and 3 . pMG407A had a 3-bp deletion of CAA in bacA that resulted in the deletion of Gln Ϫ38. This mutant maintained the ability to produce the bacteriocin. pMG407B had a 3-bp deletion of CGT in bacA that resulted in the in-frame deletion of Arg Ϫ69. pMG407C had a 1-bp deletion (A of bacA) that caused a shift in the reading frame, while pMG407D had a 2-bp deletion (AA of bacA) that caused a shift in the reading frame. The last three mutants were unable to produce bacteriocin. pMG407E had a substitution of 4 bp in the potential S.D. ribosome binding sequence of bacA that changed the AAA GGAG sequence to AATCCTG, resulting in the functional disruption of the S.D. ribosome binding sequence. pMG407F had a 1-bp G-to-C substitution in the putative start codon of bacA, which changed the start Met codon (TTG) to Phe (TTC). pMG407G had a 1-bp C-to-T substitution in the putative signal peptide processing site of bacA that converted the signal peptide processing site from L-L-A to L-L-V. Computer analysis showed that the L-L-V sequence could not be recognized as a signal peptide processing site. pMG407H had a 1-bp G-to-T substitution in another putative bacA start codon, but this substitution caused no change in the amino acid sequence. The GTG codon coding for Val could be translated as a start codon (Met), whereas a GTT codon coding for Val could not be translated as a start codon. The first three mutants were unable to produce bacteriocin. The last mutant expressed bacteriocin activity.
These results imply that bacA, which encodes 89 amino acids, starts from a TTG start codon and encodes a putative signal sequence (19 amino acid residues). The bacA protein did not show any significant homology with any other reported protein or leader peptide. These data clearly show that bacA is the determinant or structural gene for bacteriocin 32 ( Fig. 2  and 3 ). Fig. 2 . Thick lines, the 398-bp PCR product contained in pMG407 that was cloned into pAM401; thick horizontal arrow, ORF14 (bacA) in the 398-bp fragment and the direction of transcription; vertical arrow, potential signal peptidase processing site; vertical bar with an arrowhead beside P1, potential sequence upstream of the bacA promoter; Bac, bacteriocin expression against E. hirae ATCC 9790; crosses on the thick horizontal arrow, the locations where mutations were introduced. The S.D. ribosome-binding sequence is also indicated. a.a., amino acid.
Identification of the Bac 32 determinant and pTI1 type plasmid in bacteriocinogenic strains of VRE isolates. Plasmid DNAs isolated from each of the 636 VRE strains were examined for the presence of the gene encoding Bac 32 by PCR analysis with a primer specific for bacA. Of the 636 VRE strains tested, 238 (37.4%) strains gave rise to the expected 398-bp product with the bacA-specific primer. Of the 238 positive strains, 189 showed bacteriocin activity against E. faecium, E. hirae, and E. durans identical to that of Bac 32; 18 strains showed bacteriocin activities different from that of Bac 32 and a spectrum of activities wider than that of Bac 32, suggesting that these strains might encode several bacteriocins, including Bac 32; and 31 strains showed no bacteriocin activity. As described above, of the total of 277 bacteriocinogenic strains, 193 (69.7%) strains showed activity against E. faecium, E. hirae, and E. durans. The results shown here suggest that the majority (i.e., 189 [98%]) of the 193 bacteriocinogenic strains that had activity against E. faecium, E. hirae, and E. durans encoded Bac 32.
Plasmid DNAs from each of the 189 strains were examined for the presence of the pTI1 type plasmid by Southern analysis with a pTI1 plasmid probe (Fig. 4) . EcoRI fragments of plasmid DNA(s) from each of the 189 strains were separated by agarose gel electrophoresis (Fig. 4a) , tested by Southern blotting, and hybridized with pTI1 plasmid DNA (Fig. 4b) . The pTI1 plasmid DNA hybridized to EcoRI fragments of 7.8 kbp and 4.7 kbp, which correspond to the EcoRI-A and -B fragments of pTI1, respectively (Fig. 4a and b) . The EcoRI restriction profiles of plasmid DNAs from 137 (72.5%) of the 189 positive strains showed a restriction pattern identical to that of plasmid pTI1 with respect to the EcoRI fragments that hybridized to plasmid pTI1, suggesting that the majority of strains which encoded the Bac 32 bacteriocin harbored a pTI1-type plasmid.
Transferability of the pTI1-type plasmid of Bac 32 bacteriocinogenic isolates. Of the 137 strains which encoded Bac 32 and harbored a pTI1-type plasmid, 56 gentamicin-resistant strains were randomly selected to examine the transferability of the bacteriocin activity encoded on the pTI1-type plasmid by cotransfer with Gm r . Broth mating was performed between each of the 56 strains and the recipient strain E. faecium BM4105RF for 2 h at 37°C. Gentamicin-resistant transconjugants were obtained from 36 (64%) of these 56 strains at frequencies of 10 Ϫ5 to 10 Ϫ7 per donor cell on a selective agar plate containing gentamicin, rifampin, and fusidic acid. Approximately 100 transconjugants from each strain were examined for bacteriocin activity by the soft-agar assay method described in Materials and Methods. From 10 to 50% of the gentamicin-resistant transconjugants obtained from 29 (80%) of the 36 strains exhibited bacteriocin activity.
The gentamicin-resistant bacteriocinogenic transconjugants that were isolated from each of the 29 strains were shown to harbor both the gentamicin-resistant pMG1-like plasmid (45) and the pTI1-type plasmid by agarose gel electrophoresis analysis of EcoRI fragments produced by restriction digestion of the plasmid DNA(s) obtained from the transconjugants and Southern hybridization analysis with the pMG1 probe or pTI1 probe (data not shown). Plasmid DNA from the bacteriocinogenic and gentamicinresistant transconjugants was examined for the presence of the bacteriocin 32 determinant by PCR analysis with the bacAspecific primer. The strains gave rise to the expected 398-bp product specific for the bacA gene (data not shown). On the other hand, plasmid DNA from transconjugants that showed only Gm r did not give rise to the specific PCR product (data not shown). These results imply that the pTI1-type plasmids that were identified in the Bac 32-type bacteriocinogenic strains encode the Bac 32 determinant and are efficiently cotransferred or mobilized by the conjugative transfer of the gentamicin-resistant transferable plasmid (45) .
The banding patterns obtained by pulsed-field gel electrophoresis of SmaI-digested genomic DNA(s) were used to compare the 29 strains that were identified as containing the pTI1-type plasmid. The 29 strains showed 14 different banding patterns (data not shown). These data indicate that the pTI1-type plasmids have disseminated among different E. faecium strains in the clinical environment.
Identification of Bac 32 in vancomycin-sensitive E. faecium isolates. Fifty-six vancomycin-sensitive E. faecium clinical isolates that had been obtained from patients in a Japanese hospital were examined for drug resistance and Bac 32 bacteriocin activity. Forty-five (80%) isolates were drug resistant, and approximately 30% of the isolates were resistant to more than three drugs (data not shown). The number and percentage of strains resistant to the drugs tested are as follows: ampicillin, 32 strains (57.1%); chloramphenicol, 2 strains (3.6%); erythromycin, 24 strains (42.9%); gentamicin, 9 strains (16.1%); kanamycin, 19 strains (33.9%); streptomycin, 6 strains (10.7%); and tetracycline, 39 strains (69.6%). Tetracycline-resistant strains were isolated at relatively high frequencies in comparison with the frequencies of isolation of strains resistant to other drugs, but no vancomycinresistant strain was isolated. Plasmid DNAs isolated from each of the 56 isolates were examined for the presence of the Bac 32 gene by PCR analysis with a primer specific for bacA of Bac 32. A total of 22 (39.3%) of the strains tested gave rise to the expected 398-bp product with the bacA-specific primer. These 22 strains showed bacteriocin activity against E. faecalis, E. hirae, and E. durans identical to that produced by Bac 32.
Of the bacteriocinogenic strains, seven strains were randomly selected to examine the transferability of bacteriocin activity by cotransfer with drug resistance. The seven strains were confirmed to be different strains on the basis of pulsedfield gel electrophoresis analysis of SmaI-digested genomic DNAs of these strains (data not shown). The drug resistance patterns of the seven strains were as follows: ampicillin, erythromycin, gentamicin, kanamycin, and tetracycline; ampicillin, erythromycin, kanamycin, streptomycin, and tetracycline; ampicillin, erythromycin, kanamycin, and tetracycline; ampicillin, gentamicin, kanamycin, and tetracycline; ampicillin, kanamycin, and tetracycline; ampicillin and tetracycline; and ampicillin and tetracycline, respectively. Filter mating was performed between each of the seven strains and recipient strain E. faecium BM4105RF overnight at 37°C. The drug resistance characteristics of each strain were used as a selective marker for the transconjugants. Tetracycline-resistant transconjugants were obtained from each of the seven strains at frequencies of
10
Ϫ4 to 10 Ϫ6 per donor cell on a selective agar plate containing tetracycline, rifampin, and fusidic acid. No transconjugants resistant to any of the other antibiotics to which the donors exhibited resistance were obtained. Tetracycline-resistant transconjugants (approximately 100 derived from each donor strain) were examined for bacteriocin activity. Between 40 and 60% of the tetracycline-resistant transconjugants from each of the seven vancomycin-sensitive donor strains exhibited bacteriocin activity. PCR analysis of the plasmid DNA from the bacteriocinogenic and tetracycline-resistant transconjugants of each of the seven strains with the bacAspecific primer gave rise to the expected 398-bp product specific for the bacA gene (data not shown). Plasmid DNA from transconjugants that only showed tetracycline resistance did not give rise to the bacA-specific PCR product (data not shown). Each of the PCR products specific for the bacA gene was sequenced. The nucleotide sequences of the bacA genes from two of the seven test strains were identical to that of the bacA gene encoded by pTI1. The nucleotide sequences and the deduced amino acid residues of the bacA genes of the remaining five test strains revealed that a C230-to-A nucleotide substitution had occurred compared to the sequence of bacA of pTI1. This nucleotide substitution resulted in a Thr77-to-Asn amino acid substitution in the N-terminal region of BacA. A total of 46 E. faecium isolates isolated in 2002 and 2003 from healthy students were examined for Bac 32-type bacteriocin activity. Forty-one of the isolates were drug sensitive, and the remaining five strains were resistant to one or a few drugs (data not shown). Of the 46 strains, plasmid DNA isolated from one strain that was drug sensitive gave rise to the bacA-specific PCR product. The remaining 45 strains did not give rise to the PCR product.
Fifty-six E. faecalis clinical isolates were also examined by PCR analysis for the presence of the Bac 32 gene. Plasmid DNA from each of these strains did not give rise to the bacAspecific PCR product.
These results indicate that Bac 32 or a Bac 32-like bacteriocin has been specifically disseminated among VRE, as well as vancomycin-sensitive E. faecium clinical isolates.
DISCUSSION
A new bacteriocin, which was designated Bac 32, was identified in a VanA-type vancomycin-resistant E. faecium VRE200 strain. Bac 32 exhibited a relatively narrow spectrum of activity and was active against E. faecium, E. hirae, and E. durans strains. Bac 32 is encoded on plasmid pTI1 (12.5 kbp), which was efficiently mobilized for transfer to a recipient E. faecalis or E. faecium strain at a frequency of 10 Ϫ5 to 10 Ϫ7 per donor cell with the coresident conjugative gentamicin resistance plasmid (45) . The Bac 32 determinant consisted of the bacteriocin structural gene, bacA, and the immunity gene, bacB. The bacA gene encoded a deduced 89-amino-acid protein with a putative signal sequence of 19 amino acid residues at the N terminus that was predicted to give rise to a 70-amino-acid mature protein. The bacB gene encoded a deduced 55-amino-acid protein without a putative signal sequence. The deduced BacA and BacB proteins had no homology to known bacteriocins, indicating that Bac 32 is new type of bacteriocin from E. faecium.
Epidemiological studies showed that Bac 32 is representative of the Bac 32-type bacteriocins produced by a variety of VRE isolates. Many of the VRE isolates (i.e., 44% of the 636 isolates tested) were bacteriocinogenic; and a majority of these (70%) exhibited bacteriocin activity against E. faecium, E. hirae, and E. durans, which is identical to the bacteriocinogenic spectrum of Bac 32. The Bac 32 structural gene, bacA, was identified in 189 (98%) of the 193 bacteriocinogenic isolates and 189 (30%) of the 636 VanA-type VRE isolates, indicating that there is a high incidence of Bac 32 production among the VRE clinical isolates. Analysis of the plasmid DNAs from the Bac 32-producing strains suggested that the majority of the strains (i.e., 137 [72.5%] of the 189 strains) harbored a pTI1-type plasmid and that this plasmid could cotransfer to a recipient strain along with gentamicin resistance.
Previously, we showed that many of the VRE isolates (i.e., 492 [77%] of the 640 isolates) that were used in this study exhibit a high level of resistance to gentamicin and that about 50% of the gentamicin-resistant strains harbor the gentamicin resistance pMG1-like conjugative plasmid that transfers highly efficiently to a recipient strain by broth mating (45) . These data imply that the transfer of bacteriocin production encoded on the pTI1-type plasmid might result from the mobilization of the pTI1-type plasmid by the gentamicin resistance-conferring conjugative plasmid.
Bac 32 or Bac 32-like activity and the bacA gene were also identified in a high proportion (40%) of vancomycin-sensitive E. faecium clinical isolates that had been obtained from a Japanese hospital. Among these E. faecium isolates, the frequency of isolation of gentamicin-resistant strains was lower than that of isolates resistant to other drugs, and none of the isolates were VRE. Plasmid-encoded Bac 32-like activity was cotransferred with tetracycline resistance. The mechanism of the transfer has yet to be investigated.
E. faecalis and E. faecium are commonly isolated from the clinical environment (28, 35, 40) , but the frequency of isolation of E. faecalis is greater than that of E. faecium (28) . In the case of VanA-or VanB-type VRE, E. faecium is predominantly isolated from the health care environment (4) . It is known that many E. faecalis clinical isolates produce bacteriocin (9, 43, 44) and that the bacteriocin phenotype is frequently associated with the pheromone-responding conjugative plasmid of E. faecalis (9, 10, 17, 25, 32, 43, 44) . Several of the E. faecalis bacteriocins that have been identified from clinical isolates have been well characterized. Of these bacteriocins, ␤-hemolysin/ bacteriocin (cytolysin) is predominantly found in E. faecalis clinical isolates (9, 22, 24, 28, 43) . The ␤-hemolysin/bacteriocin (cytolysin) production by E. faecalis clinical isolates is frequently encoded on the E. faecalis pheromone-responsive conjugative pAD1-type plasmid (10, 25) . ␤-Hemolysin/bacteriocin (cytolysin) is associated with the virulence of E. faecalis in animal models (5, 27, 30) . An E. faecalis strain that produces ␤-hemolysin/bacteriocin (cytolysin) might have an ecological advantage over other strains in colonizing human tissue, and the pAD1-type plasmid that encodes ␤-hemolysin/bacteriocin (cytolysin) might contribute to the dissemination of the ␤-hemolysin/bacteriocin (cytolysin) determinant among E. faecalis strains. E. faecalis clinical isolates usually show multiple-drug resistance (9, 35, 40) , which provides the organism with a selective advantage within a clinical setting. These factors could result in the prevalence of ␤-hemolysin/bacteriocin (cytolysin) in E. faecalis isolates within the clinical environment.
In contrast to the E. faecalis bacteriocins, the well-characterized E. faecium bacteriocins (i.e., enterocins) are produced by food-grade organisms that have been isolated from fermented foods. These include enterocin A (1), B (3), P (7), I (15), and L50A and L50B (6) . It is characteristic of the bacteriocinogenic food-grade organisms that they are active against Listeria monocytogenes (36) , which is a frequent cause of foodborne listeriosis (19) . These food-grade bacteriocinogenic E. faecium strains might have a selective advantage in their particular ecological niche, and their ability to inhibit the growth of L. monocytogenes in food plays an important role in the microbial safety of the final product.
To our knowledge, only one bacteriocinogenic E. faecium strain, strain RC714, has been isolated from a VanA-type resistant E. faecium VRE clinical isolate and has been analyzed for bacteriocin activity (12) . The amino acid sequence of bacteriocin RC714 of E. faecium RC714 shows a high level of identity (88%) with bacteriocin 31 encoded on conjugative plasmid pYI17 of E. faecalis YI717, which is a pediocin-like bacteriocin (43) . The RC714 bacteriocin is active against E. faecalis, E. faecium, and L. monocytogenes (12) . It is not known if bacteriocin RC714-producing E. faecium strains are disseminated widely in the clinical environment.
In this study, we identified a novel bacteriocin, designated bacteriocin 32, that showed a high incidence of dissemination in vancomycin-sensitive E. faecium clinical isolates obtained from a Japanese hospital and VanA-type vancomycin-resistant E. faecium isolates obtained from a hospital in the United States. VRE are usually multiply resistant to commonly used antibiotics (4, 45) , as are vancomycin-sensitive E. faecium clinical isolates, compared to the numbers of antibiotics to which isolates from healthy students are resistant. Multiple drug resistance provides E. faecium with a selective advantage in the clinical environment, and the ability of these strains to produce bacteriocin might confer an additional advantage to the organism in this particular ecological environment. In the case of VRE, the pTI1-type plasmid is efficiently mobilized by the Gm r conjugative pMG1-type plasmid. In the case of vancomycinsensitive E. faecium isolates, Bac 32 production could be cotransferred along with tetracycline resistance. These factors could contribute to the dissemination of bacteriocin 32-producing E. faecium strains within the clinical environment of the hospital and may be responsible for their emergence as the dominant strain.
Bacteriocin 32 was not active against L. monocytogenes, which differs from the activities of the well-characterized enterocins isolated from food-grade E. faecium strains. This finding suggests that the dominant type of bacteriocin in E. faecium clinical isolates might differ from the dominant type of bacteriocin found in food-grade E. faecium isolates and that the type of bacteriocin that becomes dominant within any environment is influenced by the surrounding ecology. 
